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Abstract
Purpose Evolocumab significantly reduces low-density lipo-
protein-cholesterol (LDL-C); we investigated its effects on
LDL-C lowering in patients with mixed hyperlipidemia.
Methods We compared the efficacy and safety of evolocumab
in hypercholesterolemic patients selected from the phase 2 and
3 trials who had fasting triglyceride levels ≥1.7 mmol/L
(150 mg/dL elevated triglycerides) and <1.7 mmol/L (without
elevated triglycerides). Fasting triglyceride level ≥ 4.5 mmol/
L at screening was an exclusion criterion for these studies, but
post-enrollment triglyceride levels may have exceeded
4.5 mmol/L (400 mg/dL). Efficacy was evaluated in four
phase 3 randomized studies (n = 1148) and safety from the
phase 2 and 3 studies (n = 2246) and their open-label exten-
sion studies (n = 1698). Efficacy analyses were based on 12-
week studies, while safety analyses included data from all
available studies. Treatment differences were calculated vs.
placebo and ezetimibe after pooling dose frequencies.
Results Mean treatment difference in percentage change from
baseline in LDL-C for participants with elevated triglycerides
and those without elevated triglycerides (mean of weeks 10 and
12) with evolocumab was approximately −67 % vs. placebo
and −42 % vs. ezetimibe (all P < 0.001) compared to −6 % vs.
placebo and −39 % vs. ezetimibe, respectively. Treatment dif-
ferences for evolocumab vs. placebo and ezetimibe followed a
similar pattern for non–high-density lipoprotein (HDL-C) and
apolipoprotein B. Evolocumab was well tolerated, with bal-
anced rates of adverse events leading to discontinuation of
evolocumab vs. comparator (placebo and/or ezetimibe).
Conclusion The significant reductions of atherogenic lipids
including LDL-C, non–HDL-C, and apolipoprotein B seen
with evolocumab are similar in patients with and without
mixed hyperlipidemia.
Keywords Apolipoprotein . High-density lipoprotein .
Low-density lipoprotein-cholesterol . Proprotein convertase
subtilisin/kexin type 9 . Triglycerides
Introduction
Evolocumab (AMG 145; Repatha®; Amgen Inc., Thousand
Oaks, CA), a fully human immunoglobulin G2 monoclonal
antibody, inhibits proprotein convertase subtilisin/kexin type
9 (PCSK9)–mediated proteolytic degradation of hepatic low-
density lipoprotein (LDL) receptors resulting in more efficient
clearance of apolipoprotein B (ApoB)–containing lipoproteins
[1, 2]. In short-term and long-term placebo- and ezetimibe-
controlled phase 2 and 3 trials, evolocumab has been shown to
significantly reduce LDL-cholesterol (LDL-C) and other
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atherogenic lipid fractions in participants with varying
lipid phenotypes, cardiovascular risk, and baseline statin
therapy [3–13]. In patients with mixed hyperlipidemia
(characterized by elevated triglyceride and cholesterol
levels), increased serum concentrations of remnant-like
particles derived from either chylomicrons or very low–
density lipoprotein (VLDL) are observed [14]. Clearance
of remnant lipoproteins is complex and occurs through a
variety of receptors, including the LDL-receptor [15].
While inhibition of PCSK9 with evolocumab has been
shown to significantly reduce serum LDL-C, whether this
effect would be similar in patients with higher circulating
levels of triglycerides and remnant-like lipoproteins has
not been evaluated.
In this analysis, we compared the efficacy and safety of
evolocumab in participants from the phase 2 and 3 trials with
mixed hyperl ipidemia—baseline elevated LDL-C
(≥2.0 mmol/L [75 mg/dL]) and elevated fasting triglycerides
(≥1.7 mmol/L [150 mg/dL] to <4.5 mmol/L [400 mg/dL]) and
those with only hypercholesterolemia—without elevated
fasting triglyceride levels (<1.7 mmol/L). Additional compar-
ison on the percentage of high-risk participants meeting LDL-
C, non–high-density lipoprotein (HDL-C), and ApoB thresh-
olds between the two groups was conducted.
Methods
Study Design
Efficacy was evaluated in four phase 3 randomized studies
(n = 1148) [5, 9, 11, 12] and safety from the phase 2 and 3
studies (n = 2246) and their open-label extension studies
(n = 1698) (Fig. 1) [3–13]. Efficacy analyses were based on
12-week phase 3 studies, while safety analyses included data
from all available studies. Amgen sponsored and designed the
trials and was responsible for data collection and analysis.
Informed consent was obtained from each patient, and the
study protocol conforms to the ethical guidelines of the
Declaration of Helsinki as reflected in approval by the insti-
tution’s human research committee.
Participants
Patients were eligible if they were adults aged 18 to 75 (phase
2 studies) or 18 to 80 (phase 3 studies) years with an LDL-C
level of ≥2.0 mmol/L (75 mg/dL) and triglyceride
level < 4.5 mmol/L (400 mg/dL). A fasting triglyceride level
of ≥4.5 mmol/L (400 mg/dL) at screening was an exclusion
criterion for these studies, but post-enrollment triglyceride
3146 participants in four phase 3 studies of evolocumab 
randomized and received at least one dose of study drug
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Fig. 1 Participant disposition.GAUSSGoal Achievement After Utilizing
an Anti-PCSK9 Antibody in Statin Intolerant Subjects, HeFH heterozy-
gous familial hypercholesterolemia, LAPLACE LDL-C Assessment With
PCSK9Monoclonal Antibody Inhibition CombinedWith Statin Therapy,
MENDEL Monoclonal Antibody Against PCSK9 to Reduce Elevated
LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing
Lipid Levels, Q2W every 2 weeks, QM every month, RUTHERFORD
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial
Hypercholesterolemia Disorder, TG triglycerides
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levels may have exceeded 4.5 mmol/L. Full details of the
exclusion criteria have been published elsewhere [16].
Efficacy and Safety Endpoints
Efficacy analyses were based on 12-week phase 3 studies [5,
9, 11, 12]. Treatment differences were calculated vs. placebo
and ezetimibe by pooling the data from evolocumab biweekly
and monthly dosing groups. The co-primary endpoints were
mean percentage change from baseline in LDL-C at weeks 10
and 12 and percentage change from baseline in LDL-C at
week 12. Secondary endpoints included mean percentage
changes in non–HDL-C, ApoB, HDL-C, and triglycerides.
The mean percentage reduction from baseline in LDL-C at
weeks 10 and 12 and percentage change from baseline in
LDL-C at week 12 were not substantially different in the stud-
ies. The present analysis therefore reports mean percentage
reduction from baseline in LDL-C, non–HDL-C, ApoB, and
HDL-C at weeks 10 and 12. Safety analyses included data
from all available studies.
Statistical Analysis
The co-primary and co-secondary efficacy endpoints
were analyzed using a repeated measures linear model,
with terms for treatment group, study, the interaction of
treatment and study, baseline LDL-C, dose frequency,
visit, and the interaction of treatment with visit. The
studies used for this analysis compared evolocumab vs.
placebo, vs. ezetimibe, or vs. placebo or ezetimibe.
Therefore, the analyses to assess the treatment effect of
evolocumab vs. placebo only included studies that had a
placebo treatment arm, and likewise for the comparison
vs. ezetimibe. Cochran Mantel Haenszel tests or
chi-squared tests were used for binary endpoints.
Descriptive statistics were used to assess the incidence
of adverse events and raised laboratory values.
Statistical analysis was performed using SAS version
9.3 (SAS Institute, Cary, NC). Adverse events were cod-
ed using Medical Dictionary for Regulatory Activities
version 17.0.
Table 1 Baseline demographics, disease characteristics, and lipid levels
Characteristic TG ≥1.7 mmol/L at screening
(N = 1148)
TG <1.7 mmol/L at screening
(N = 1998)
P-valuea
Age, mean (SD) (years) 57.4 (10.7) 58.0 (11.5) NS
Female sex, n (%) 511 (44) 1042 (52) <0.05
Race, n (%) <0.05
White 1072 (93) 1806 (90)
Asian 40 (4) 68 (3)
Black or African American 20 (2) 104 (5)
Other 16 (1) 20 (1)
Coronary artery disease, n (%) 242 (21) 380 (19) NS
Type 2 diabetes mellitus, n (%) 197 (17) 183 (9) <0.05
≥2 cardiovascular risk factors, n (%) 560 (49) 610 (31) <0.05
Metabolic syndrome without type 2 diabetes,b n (%) 599 (52) 390 (20) <0.05
LDL-C,b mean (SD) (mmol/L)c 3.4 (1.4) 3.3 (1.2) NS
TG, median (Q1, Q3) (mmol/L) 2.0 (1.6, 2.5) 1.1 (0.9, 1.4) <0.05
HDL-C, mean (SD) (mmol/L) 1.2 (0.3) 1.5 (0.4) <0.05
Non–HDL-C, mean (SD) (mmol/L) 4.4 (1.5) 3.9 (1.3) <0.05
ApoB, mean (SD) (g/L) 1.1 (0.3) 1.0 (0.3) <0.05
Statin treatment 825 (72) 1450 (73) NS
High-intensity statin treatment 366 (32) 658 (33)
ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NS not significant, Q quartile, SD
standard deviation, TG triglycerides
aMeans were compared using t-tests. For TGs, medians were compared using a Wilcoxon test. Binary data was compared using a chi-squared test
bMetabolic syndrome is defined as having three or more of the following factors: elevated waist circumference (non-Asian: men ≥102 cm, women
≥88 cm; Asian: men ≥90 cm, women ≥80 cm), TG ≥1.7 mmol/L, low HDL-C (<1.0 mmol/L in men and <1.3 mmol/L in women), systolic blood
pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or hypertension, or fasting glucose ≥100 mg/dL
c LDL-C was based on calculated values unless calculated LDL-C was <1.0 mmol/L or TG were >4.5 mmol/L, in which case the ultracentrifugation
LDL-C value from the same blood sample was used instead, if available
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Results
Baseline demographics, clinical characteristics, and lipids in
patients with and without elevated triglycerides are shown in
Table 1. Elevated triglyceride levels (≥1.7 mmol/L [150 mg/
dL]) were more common in men, and there were significant
differences by the participant’s race. This subgroup also had a
greater prevalence of type 2 diabetes and multiple cardiovas-
cular disease (CVD) risk factors, as well as increased levels of
non–HDL-C and ApoB but lower HDL-C. Baseline mean
(standard deviation) LDL-C was similar in patients with (3.4
[1.4] mmol/L) (129.9 mg/dL [52.4]) and without (3.3 [1.2]
mmol/L) (127.6 [46.4]) elevated triglycerides. The propor-
tions of participants on any statin treatment (72 % [n = 825]
with elevated triglycerides, 73 % [n = 1450] without elevated
triglycerides) and high-intensity statin treatment (32 %
[n = 366], 33 % [n = 658]) were similar between participants
with or without elevated triglycerides.
Efficacy Endpoints
The treatment difference in mean percentage change from
baseline to the mean of weeks 10 and 12 in LDL-C for
evolocumab-treated participants with elevated triglycerides
was approximately −67 % vs. placebo and −42 % vs.
ezetimibe compared to −65 % vs. placebo and −39 % vs.
ezetimibe in participants without elevated triglyceride levels
(all P < 0.001) (Fig. 2a, Tables 2 and 3). Treatment differences
for evolocumab vs. placebo and ezetimibe among those with
or without elevated triglycerides also followed a similar pat-
tern for non–HDL-C, ApoB, triglycerides, and HDL-C
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* P<0.001
* P<0.001
Fig. 2 Effects of evolocumab vs.
placebo or ezetimibe on (a) LDL-
C levels and (b) other lipids in
participants with or without ele-
vated TG. LDL-C was
based on calculated values
unless calculated LDL-C
was <1.0 mmol/L or TG were
>4.5 mmol/L, in which case the
ultracentrifugation LDL-C value
from the same blood sample was
used instead, if available. ApoB
apolipoprotein B, HDL-C high-
density lipoprotein cholesterol,
LDL-C low-density lipoprotein
cholesterol, SE standard error,
TG triglycerides
*P < 0.001
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A greater proportion of participants with elevated triglyc-
erides were classed as National Cholesterol Education
Program (NCEP) high risk (41 %) compared with participants
without elevated triglycerides (30 % NCEP high risk). We
analyzed the proportion of NCEP III–high-risk participants
meeting targets for LDL-C, non–HDL-C, and ApoB as pro-
posed by several professional societies. A similarly high pro-
portion of evolocumab-treated, NCEP III–high-risk patients
with and without elevated triglycerides achieved the LDL-C
target of <1.8 mmol/L (70 mg/dL) (82 % vs. 81 %, respec-
tively) and <2.6 mmol/L (100 mg/dL) (92 % vs. 92%, respec-
tively). Significantly more participants without elevated tri-
glycerides achieved the ApoB targets than participants with
elevated triglycerides (P < 0.05). Additionally, significantly
more participants without elevated triglycerides achieved the
non–HDL-C target of <2.6 mmol/L (100 mg/dL) than partic-
ipants with elevated triglycerides (85 % vs. 77 %, P < 0.05)
(Table 4). Further breakdown of the treatment differences for
meeting lipid and ApoB goals with evolocumab vs. placebo or
ezetimibe with or without elevated triglycerides is shown in
Fig. 3 (NCEP III–high-risk participants only).
Safety Analyses
Evolocumab was generally well tolerated. Rates of adverse
events were balanced between evolocumab vs. placebo or
ezetimibe (Table 5).
Discussion
This analysis evaluated the effects of evolocumab in participants
with mixed hyperlipidemia (hypercholesterolemia with triglyc-
erides ≥1.7 mmol/L [150 mg/dL]) and participants with hyper-
cholesterolemia but without elevated triglycerides (<1.7mmol/L
Table 3 LDL-C and other atherogenic lipids at baseline and at the mean of weeks 10 and 12 (ie, follow-up), participants with TG <1.7 mmol/L
Placebo (N = 275) Ezetimibe (N = 192) Evolocumab (N = 681)
Baseline Follow-up Baseline Follow-up Baseline Follow-up
LDL-Ca 2.98 (1.08) 3.02 (0.08) 3.73 (1.45) 2.93 (0.09) 3.42 (1.40) 1.29 (0.03)
TG 1.92 (1.47, 2.41) 1.88 (1.45, 2.45) 2.12 (1.69, 2.71) 1.91 (1.35, 2.44) 1.99 (1.57, 2.54) 1.63 (1.28, 2.13)
HDL-C 1.23 (0.34) 1.20 (0.02) 1.18 (0.30) 1.18 (0.02) 1.22 (0.33) 1.30 (0.01)
Non-HDL-C 3.94 (1.24) 3.99 (0.08) 4.77 (1.62) 3.88 (0.11) 4.41 (1.52) 2.04 (0.04)
ApoBb 0.98 (0.27) [271] 1.00 (0.02) [271] 1.17 (0.36) [191] 0.99 (0.02) [187] 1.09 (0.34) [678] 0.54 (0.01) [663]
Baseline values are mean (standard deviation) and the follow-up values are mean (standard error)—except for TG for which both baseline and follow-up
values are median (interquartile range)
ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides
a LDL-C was based on calculated values unless calculated LDL-C was <1.0 mmol/L or TG were >4.5 mmol/L, in which case the ultracentrifugation
LDL-C value from the same blood sample was used instead, if available
b The number of participants with available data are, from left to right, 271, 271, 191, 187, 678, and 663
Table 2 LDL-C and other atherogenic lipids at baseline and at the mean of weeks 10 and 12 (ie, follow-up), participants with TG ≥1.7 mmol/L
Placebo (N = 546) Ezetimibe (N = 285) Evolocumab (N = 1167)
Baseline Follow-up Baseline Follow-up Baseline Follow-up
LDL-Ca 3.17 (1.07) 3.23 (0.05) 3.50 (1.23) 2.83 (0.07) 3.34 (1.28) 1.37 (0.03)
TG 1.07 (0.84, 1.38) 1.11 (0.88, 1.48) 1.14 (0.88, 1.40) 1.10 (0.84, 1.38) 1.11 (0.87, 1.40) 0.96 (0.78, 1.24)
HDL-C 1.52 (0.47) 1.49 (0.02) 1.52 (0.43) 1.51 (0.02) 1.50 (0.44) 1.57 (0.01)
Non-HDL-C 3.70 (1.12) 3.79 (0.05) 4.05 (1.28) 3.36 (0.08) 3.88 (1.32) 1.81 (0.03)
ApoBb 0.93 (0.26) 0.94 (0.01) 0.99 (0.27) 0.86 (0.02) 0.96 (0.28) 0.49 (0.01)
Baseline values are mean (standard deviation) and the follow-up values are mean (standard error)—except for TG for which both baseline and follow-up
values are median (interquartile range)
ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides
a LDL-C was based on calculated values unless calculated LDL-C was <1.0 mmol/L or TG were >4.5 mmol/L, in which case the ultracentrifugation
LDL-C value from the same blood sample was used instead, if available
b The number of patients with available data are, from left to right, 542, 531, 283, 277, 1161, and 1145
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[150 mg/dL]). Efficacy and safety of evolocumab treatment
were similar in both groups.
The American Heart Association/American College of
Cardiology guidelines recognize LDL as the major atherogen-
ic lipoprotein and consequently identify LDL-C as the prima-
ry target of therapy [17]. However, triglyceride-rich particles
(e.g., VLDL) also increase the risk of CVD, and the combina-
tion of high LDL-C coupled with high triglycerides represents
a particularly atherogenic phenotype [18–20]. Consequently,
professional societies have endorsed [18, 20, 21] non–HDL-C
(LDL-C + VLDL-C) as the preferred target in patients with
mixed hyperlipidemia [22]. Additional evidence supporting
the contribution of other lipoproteins, beyond LDL, to in-
creased cardiovascular risk includes an analysis of statin trials,
which demonstrated that on-treatment levels of non–HDL-C
are more strongly associated with future risk of atherosclerotic
CVD events than LDL-C [23]. Also, in statin-treated subjects,
some studies have shown that ApoB provides equivalent or
superior discrimination of risk [24–28]. Furthermore, patients
with an elevated triglyceride concentration have smaller LDL
particles resulting in less efficient clearance via hepatic LDL
receptors [29, 30]. This leads to higher LDL particle concen-
trations in patients with elevated triglycerides than would be
predicted based on the level of LDL-C [29, 31]. Thus, several
consensus documents propose a tiered approach for the as-
sessment of treatment targets (LDL-C, non–HDL-C, and
ApoB, or LDL particles) [32, 33].
Prior studies of evolocumab demonstrated significant
LDL-C reductions of up to 75 % compared to placebo
(in participants taking maximally tolerated statins), but
its effect on patients with mixed hyperlipidemia was not
formally evaluated. The results of this analysis demon-
strate that cholesterol reduction with evolocumab is simi-





























































Fig. 3 Treatment differences for meeting lipid and ApoB goals with
evolocumab vs. placebo or ezetimibe in NCEP III–high-risk
participants only with or without elevated TG. The numbers of
participants represented were as follows: ≥1.7 mmol/L, 220 vs 93
(evolocumab vs placebo) and 131 vs 88 (evolocumab vs ezetimibe);
<1.7 mmol/L, 323 vs 164 (evolocumab vs placebo) and 158 vs 65
(evolocumab vs ezetimibe). LDL-C was based on calculated values un-
less calculated LDL-Cwas <40mg/dL or TGwere >400mg/dL, in which
case the ultracentrifugation LDL-C value from the same blood sample
was used instead, if available. ApoB apolipoprotein B, LDL-C low-
density lipoprotein cholesterol, NCEP National Cholesterol Education
Program, HDL-C high-density lipoprotein cholesterol, TG triglycerides
Table 4 Percentage of NCEP–high-risk participants treated with
evolocumab meeting lipid, non–HDL-C, and ApoB thresholdsa
Goala TG ≥1.7 mmol/L,
% (n = 284)
TG <1.7 mmol/L,
% (n = 368)
LDL-C < 1.8 mmol/Lb 82 81
LDL-C < 2.6 mmol/Lb 92 92
Non–HDL-C < 2.6 mmol/L 77 85*
Non–HDL-C < 3.4 mmol/L 90 93
ApoB <0.8 g/L 85 93*
ApoB <0.9 g/L 90 94*
ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol, NCEP National Cholesterol
Education Program, TG triglycerides
a Thresholds met at mean of weeks 10 and 12
b LDL-C was based on calculated values unless calculated LDL-C was
<1.0 mmol/L or TG were >4.5 mmol/L, in which case the ultracentrifu-
gation LDL-C value from the same blood sample was used instead, if
available
*P < 0.05, TG ≥1.7 mmol/L vs. TG <1.7 mmol/L based on chi-squared
tests
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reductions of 67% and 65% vs. placebo, respectively. Similar
to the reductions in LDL-C, evolocumab was equally effica-
cious in lowering non–HDL-C and ApoB in hypercholester-
olemic participants regardless of whether the triglyceride level
was elevated or not. Also shown is that 80 % to 90 % of
participants achieved LDL-C, non–HDL-C, and ApoB thresh-
olds (LDL-C < 1.8 mmol/L, non–HDL-C < 3.4 mmol/L, and
ApoB <0.8 g/L targets), with the only exception in that 77 %
of participants with elevated triglycerides achieved non–
HDL-C < 2.6 mmol/L.
Strengths of our analysis include the broad group of partic-
ipants studied including those from monotherapy, statin combi-
nation therapy, statin-intolerant and heterozygous familial hy-
percholesterolemia evolocumab trials as well as participants
from placebo- and ezetimibe-controlled studies. Several limita-
tions of the current study are also noted. One limitation is that
we pooled data across randomized studies as a post-hoc analy-
sis. Additionally, we did not analyze specimens for lipoprotein
particle size and concentration in order to investigate the effi-
cacy of evolocumab on the distribution of VLDL and LDL
particles. Although we observed equivalent efficacy of
evolocumab in participants with fasting triglycerides
<4.52 mmol/L that are mainly transported in medium and small
VLDL particles, none of the phase 2 or 3 studies included
participants with baseline fasting triglycerides ≥4.52 mmol/L
(400 mg/dL). Future studies would be useful to investigate
the efficacy of evolocumab in patients with higher triglycerides
that are transported in large VLDL particles (>4.5 mmol/L
to <9.6 mmol/L) and chylomicrons.
Conclusions
In participants with elevated triglycerides, evolocumab was
well tolerated and resulted in statistically and clinically signif-
icant reductions of LDL-C, non–HDL-C, and ApoB levels vs.
placebo and ezetimibe. Similar treatment effects were seen in
participants without elevated triglycerides.
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Table 5 Safety in participants with or without elevated triglycerides













All AEs 282 (47.6) 574 (50.5) 124 (54.6) 155 (47.4) 699 (49.0) 1414 (52.0)
Grade ≥2a 147 (24.8) 290 (25.5) 64 (28.2) 57 (17.4) 317 (22.2) 630 (23.2)
Grade ≥3a 26 (4.4) 34 (3.0) 8 (3.5) 4 (1.2) 57 (4.0) 93 (3.4)
Grade ≥4a 4 (0.7) 3 (0.3) 0 (0.0) 0 (0.0) 7 (0.5) 17 (0.6)
Serious AEs 16 (2.7) 25 (2.2) 5 (2.2) 2 (0.6) 46 (3.2) 65 (2.4)
Leading to discontinuation
of study drug
8 (1.4) 17 (1.5) 13 (5.7) 11 (3.4) 21 (1.5) 54 (2.0)
Serious 1 (0.2) 4 (0.4) 0 (0.0) 0 (0.0) 3 (0.2) 13 (0.5)
Non-serious 7 (1.2) 14 (1.2) 13 (5.7) 11 (3.4) 19 (1.3) 44 (1.6)
Fatal AEs 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.1)
ALT or AST >3 × ULN 5 (0.9) 12 (1.1) 5 (2.2) 0 (0.0) 9 (0.6) 9 (0.3)
ALT or AST >5 × ULN 2 (0.3) 5 (0.4) 0 (0.0) 0 (0.0) 3 (0.2) 3 (0.1)
CK >5 × ULN 3 (0.5) 8 (0.7) 3 (1.3) 1 (0.3) 4 (0.3) 23 (0.9)
CK >10 × ULN 2 (0.3) 3 (0.3) 0 (0.0) 1 (0.3) 1 (0.1) 8 (0.3)
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, TG triglycerides, ULN upper limit of normal
a Graded according to Common Terminology Criteria for Adverse Events
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Appendix: Clinical Trial Registration Identifiers
All studies used for this analysis were registered at ClinicalTrials.gov. The
following lists display the identifiers for each study.
Phase 3, 12-week studies (efficacy and safety): NCT01763866,
NCT01763827, NCT01763905, NCT01763918
Other phase 2 and 3 studies (safety): NCT01375751, NCT01375764,
NCT01375777, NCT01380730, NCT01516879, NCT01763827,
NCT01953328
Open-label extension studies (safety): NCT01849497, NCT01879319
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